^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Shan Ke Yu (socazolimab)

    i
    Other names: STI-A1014, ZKAB 001, ZKAB001, STI A1014, STIA1014
    Company:
    Lee's Pharm, Sorrento
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    2ms
    Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma. (PubMed, Oncologist)
    Socazolimab combined with nab-paclitaxel has shown good safety and promising antitumor activity as first-line therapy in patients with advanced urothelial carcinoma.
    P1 data • Journal • Combination therapy • Metastases
    |
    PD-1 (Programmed cell death 1)
    |
    albumin-bound paclitaxel • Shan Ke Yu (socazolimab)
    6ms
    Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer (clinicaltrials.gov)
    P3, N=440, Not yet recruiting, Lee's Pharmaceutical Limited
    New P3 trial • Metastases
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel • Shan Ke Yu (socazolimab)
    11ms
    A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With ES-SCLC (clinicaltrials.gov)
    P3, N=498, Completed, Lee's Pharmaceutical Limited | Recruiting --> Completed
    Trial completion
    |
    PD-L1 expression
    |
    carboplatin • etoposide IV • Shan Ke Yu (socazolimab)
    2years
    First-in-maintenance therapy for localized high-grade osteosarcoma: an open-label phase I/II trial of the anti-PD-L1 antibody ZKAB001. (PubMed, Clin Cancer Res)
    Switching to maintenance using ZKAB001 showed an acceptable safety profile and provided preliminary evidence of clinical activity in localized osteosarcoma patients.
    P1/2 data • Journal
    |
    MSI (Microsatellite instability)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    Shan Ke Yu (socazolimab)
    over3years
    A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Recurrent or Metastatic Cervical Cancer (clinicaltrials.gov)
    P1, N=101, Recruiting, Lee's Pharmaceutical Limited | N=15 --> 101
    Clinical • Enrollment change • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    PD-L1 expression
    |
    Shan Ke Yu (socazolimab)